64results about How to "Preserve immunogenicity" patented technology

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.

The invention concerns the treatment of obesity, in particular abdominal visceral obesity. More specifically, the invention concerns the use of selective 15-lipoxygenase (LO) inhibitors for preparing medicines useful in the treatment of obesity, or at least abdominal visceral obesity, and/or its consequences.

The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.

The invention belongs to the field of biological medicines of veterinarians and relates to an avian infectious bronchitis virus vaccine strain (HF2 strain) as well as application and an application effect of the vaccine strain in prevention and control of avian infectious bronchitis. The microbial preservation number of the vaccine strain is 7708. The vaccine strain disclosed by the invention is good in security and has a good protection effect on the avian infectious bronchitis. The vaccine strain can be used for preparing an inactivating single vaccine or combined vaccine for preventing and controlling the avian infectious bronchitis; a virus strain can be used for preparing an attenuated vaccine or combined vaccine for preventing and controlling the avian infectious bronchitis after being attenuated.

The invention discloses a bacterial polysaccharide protein conjugate vaccine using a hepatitis B surface antigen as carrier protein and a preparation method of the bacterial polysaccharide protein conjugate vaccine. According to the vaccine, protein is the hepatitis B surface antigen, and a bacterial polysaccharide is selected from any one or more of a haemophilus influenza type b polysaccharide, group A, group C, group Y and group W135 meningococcal polysaccharides, a salmonella typhi type Vi polysaccharide, a group B streptococcus type Ia polysaccharide and the like, pneumococcus serotype type 1, 2 and the like, and salmonella paratyphi type A or salmonella paratyphi type B. Animal experiments show that the antibody positive conversion rates of the bacterial polysaccharide and the hepatitis B surface antigen in the vaccine are both more than 85%, so that the vaccine is relatively high in antibody positive conversion rate; carrier protein plays a role in transforming the bacterial polysaccharide from a T-cell-independent antigen into a T-cell-dependent antigen, and also can be used for preventing diseases caused by hepatitis B virus; and by adopting the bacterial polysaccharide protein conjugate vaccine disclosed by the invention, the problem of performing immunization inoculation on infants and young children under 2 years old can be solved, the function of one injection with multiple immune effects also can be achieved, and the use crowd and coverage rate of the vaccine can be expanded.

The invention provides a clostridium perfringen alpha toxin genetic engineering vaccine and a preparation method thereof. Compared with wild type alpha toxins, clostridium perfringen alpha toxin recombination protein is characterized in that the 176th site histidine of an amino acid sequence is mutated to obtain asparagine. The clostridium perfringen alpha toxin genetic engineering vaccine is prepared from detoxifcation clostridium perfringen alpha toxin recombination protein of self-induction secretory expression. The vaccine has the advantages of being safer, better in immune efficacy, simpler in technology, lower in cost and the like, and can effectively solve the problems that in the prior art, the production technology of the vaccine is complexer, and the cost is higher.

The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.

The invention discloses low-allergenicity fish allergen parvalbumin, and a preparation method and application thereof. The low-allergenicity fish allergen parvalbumin has galactosylated modification of three amino acid residues, i.e., the 88th lysine residue, the 97th lysine residue and the 108th lysine residue. Moreover, the low-allergenicity fish allergen parvalbumin has galactosylated modification of the 46th lysine residue, the 55th lysine residue and the 84th lysine residue. The low-allergenicity fish allergen parvalbumin has the characteristic of low allergenicity and maintains immunogenicity. The low-allergenicity fish allergen parvalbumin is prepared by uniformly mixing parvalbumin and a sugar solution and then successively subjecting the obtained mixture to freeze drying, a Maillard reaction, redissolving and sugar removal, and can be used for preparing a drug for preventing allergen sensitization, especially fish allergen sensitization and a low-allergenicity foodstuff, especially a low-allergenicity fish-related foodstuff.

The invention discloses an attenuated infectious bursal disease virus, which has a preservation name of: infectious bursal disease virus IBDV/1F, and is preserved in China Center for Type Culture Collection at Wuhan University in Wuhan, China. The preservation number is CCTCC NO: V201834, and the preservation date: July 3, 2018. The invention also provides the use of the attenuated infectious bursal disease virus in preparation of vaccines. The viral strain does not cause bursal damage in chickens and can induce high titer antibodies directed at infectious bursal disease virus. The vaccine canresist the attack of virulent strains and has no influence on the development of chickens.

The invention relates to the technical field of veterinary biology, and particularly relates to a porcine rotavirus recombinant protein, a recombinant adenovirus expressing same protein and application. The recombinant protein is formed by connecting a porcine rotavirus type 5 VP7 protein and a porcine rotavirus type 9 VP8 protein, and specifically comprises an amino acid sequence shown as SEQ ID NO: 1. Gene sequences of coding genes of the porcine rotavirus type 5 VP7 protein and the porcine rotavirus type 9 VP8 protein are constructed into an adenovirus expression vector, codon optimization is carried out, and the recombinant adenovirus for the porcine rotavirus is prepared. The structure and function of the target protein expressed by the recombinant adenovirus are completely consistent with those of the natural state, and the recombinant adenovirus has high safety and immunogenicity.

The invention relates to the field of biotechnology, in particular to recombinant baculovirus expressing senecavirus VP2 gene and a preparation method and application thereof. The recombinant baculovirus comprises one or more copies of senecavirus VP2 protein encoding gene. The invention further provides a senecavirus subunit vaccine which comprises the recombinant baculovirus expressed senecavirus VP2 protein. Accordingly, by means of artificial codon optimization, high-level and high-purity expression of senecavirus VP2 protein is achieved, and the immunogenicity of the VP2 protein is retained to the maximum extend. The senecavirus subunit vaccine has the excellent immunogenicity and high safety, and an ideal immune protection effect is achieved for infection of senecavirus.

The invention relates to a pseudorabies virus TK, gE, gI and gG gene deletion strain as well as a preparation method and an application thereof. A CRISPR/Cas9 mediated homologous recombination technology specifically comprises the steps that CRISPR/Cas9 serves as a medium to break DNA double strands, then a homologous recombination method is used, homologous sequences transferred into cells are supplemented to notches, DNA double strand repairing is conducted, genome editing is completed, accurate fixed-point editing can be conducted according to the will of a researcher, the gene editing efficiency is greatly improved, and the research and development period of vaccine can be shortened. According to the present invention, the partial sequences of the virulence-related genes TK, gE and gIand the immunosuppression-related gene gG of the pseudorabies virus epidemic strain are deleted by using the technology to obtain the TK, gE, gI and gG gene deleted strain, and the vaccine of the genedeleted strain has advantages of high safety, good hereditary stability, good immunoprotection effect and the like.

The invention discloses a porcine pseudorabies virus with six-gene deletion, a porcine pseudorabies vaccine and a preparation method, and relates to the field of animal biological products. The accession number of the porcine pseudorabies virus with six-gene deletion provided by present invention is CGMCC No:16290. The porcine pseudorabies virus with six-gene deletion lacks six genes, the pathogenicity is removed, and the immunogenicity is effectively retained. When in use, the vaccine prepared by the porcine pseudorabies virus can induce a higher dose of interferon in the body, and has a better immune effect in emergency immunization.

The present invention discloses a marked Pestivirus suis C strain expressing enhanced green fluorescent protein and construction method and application thereof, and belongs to construction and application of marked Pestivirus suis C strain. A C strain infectious clone is used as a skeleton, the Pestivirus suis Shimen strain Npro protein is used to substitute a C strain Npro protein, then an EGFP gene is introduced between No. 13 and 14 amino acids of the Npro protein to obtain an marked Pestivirus suis C strain expressing enhanced green fluorescent protein, wherein the strain has microbial preservation number: CGMCC No. 12039. The marked Pestivirus suis C strain can stably express EGFP gene, is successfully observed with green fluorescence, retains biological properties and immunogenicity of the parental viruses, and can be applied to the preparation of marked vaccines for prevention of Pestivirus suis. The present invention confirms that the C strain Npro protein can be modified to obtain marked Pestivirus suis, so as to lay foundation for the development of marked C strain vaccine.

The invention discloses a recombinant porcine pseudorabies virus and application thereof and a recombinant porcine live pseudorabies vaccine, and relates to the field of biological products for animals. The recombinant porcine pseudorabies virus provided by the invention has the collection number of CGMCC No: 16289. The recombinant porcine pseudorabies virus is obtained after artificial transformation, the pathogenicity thereof is removed, pseudorabies virus TK, gI, gE, 11K and 28K genes are deleted, and fusion protein obtained through fusion of porcine epidemic diarrhea virus S truncated protein and porcine CD40L protein can be expressed. After a pig is immunized by the recombinant porcine live pseudorabies vaccine prepared by using the recombinant porcine pseudorabies virus, the pig canacquire the immunity against the porcine epidemic diarrhea virus challenge and the porcine pseudorabies virus challenge. The recombinant porcine live pseudorabies vaccine has a relatively good immuneeffect and has a broad application prospect.